Meeting
2019 ASCO Annual Meeting
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.
Authors
David M. O'Malley
The Ohio State University, Columbus, OH
David M. O'Malley , Ursula A. Matulonis , Michael J. Birrer , Cesar Martin Castro , Ignace Vergote , Lainie P. Martin , Gina Mantia-Smaldone , Lucy Gilbert , Antonio González-Martín , Raquel Bratos , Brooke Esteves , Karim S. Malek , Kathleen N. Moore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02606305
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5520)
DOI
10.1200/JCO.2019.37.15_suppl.5520
Abstract #
5520
Poster Bd #
343
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
First Author: David M. O'Malley
First Author: David M. O'Malley
Poster
2022 ASCO Annual Meeting
A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.
First Author: Stephanie Lheureux
Poster
2022 ASCO Annual Meeting
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
First Author: Ursula A. Matulonis